ATE537832T1 - Mittel zur prävention und behandlung von lebererkrankungen mit einem pyrazolopyrimidin- derivat - Google Patents
Mittel zur prävention und behandlung von lebererkrankungen mit einem pyrazolopyrimidin- derivatInfo
- Publication number
- ATE537832T1 ATE537832T1 AT05808627T AT05808627T ATE537832T1 AT E537832 T1 ATE537832 T1 AT E537832T1 AT 05808627 T AT05808627 T AT 05808627T AT 05808627 T AT05808627 T AT 05808627T AT E537832 T1 ATE537832 T1 AT E537832T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrazolopyrimidine derivative
- present
- prevention
- treatment
- preventing
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title abstract 5
- 208000019423 liver disease Diseases 0.000 title abstract 3
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 2
- 208000007232 portal hypertension Diseases 0.000 abstract 2
- 210000003240 portal vein Anatomy 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000004024 hepatic stellate cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050050033 | 2005-06-10 | ||
| PCT/KR2005/003526 WO2006132460A1 (en) | 2005-06-10 | 2005-10-21 | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE537832T1 true ATE537832T1 (de) | 2012-01-15 |
Family
ID=37498629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05808627T ATE537832T1 (de) | 2005-06-10 | 2005-10-21 | Mittel zur prävention und behandlung von lebererkrankungen mit einem pyrazolopyrimidin- derivat |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8796286B2 (de) |
| EP (1) | EP1888074B1 (de) |
| JP (1) | JP4879977B2 (de) |
| KR (1) | KR100914445B1 (de) |
| CN (1) | CN101193636B (de) |
| AT (1) | ATE537832T1 (de) |
| AU (1) | AU2005332719B2 (de) |
| BR (1) | BRPI0520209A2 (de) |
| CA (1) | CA2611638C (de) |
| CY (1) | CY1112637T1 (de) |
| DK (1) | DK1888074T3 (de) |
| ES (1) | ES2376628T3 (de) |
| IL (1) | IL187678A (de) |
| MX (1) | MX2007015365A (de) |
| NO (1) | NO20076053L (de) |
| NZ (1) | NZ564369A (de) |
| PT (1) | PT1888074E (de) |
| RU (1) | RU2369392C2 (de) |
| UA (1) | UA86528C2 (de) |
| WO (1) | WO2006132460A1 (de) |
| ZA (1) | ZA200800180B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101600452B (zh) * | 2006-12-28 | 2013-01-02 | 金英赛得科技有限公司 | 用于预防肝功能障碍的包含蜘蛛酶的药物组合物 |
| WO2010118367A2 (en) * | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| KR20130026504A (ko) * | 2010-07-14 | 2013-03-13 | 큠버랜드 에멀징 테크놀로지스 아이앤씨 | 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법 |
| WO2014011925A2 (en) | 2012-07-11 | 2014-01-16 | University Of Mississippi Medical Center | Method for the detection and staging of liver fibrosis from image acquired data |
| US12161632B2 (en) | 2014-05-16 | 2024-12-10 | Cumberland Pharmaceuticals Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
| JP6273072B2 (ja) | 2014-05-16 | 2018-01-31 | カンバーランド ファーマシューティカルズ，インコーポレーテッド | イフェトロバンにより心臓線維症を治療する組成物及び方法 |
| KR102448406B1 (ko) | 2015-06-30 | 2022-09-27 | 큠버랜드 파마슈티컬즈 인코포레이티드 | Ａｅｒｄ/천식에서 트롬복산 수용체 길항제 |
| EP3454850B1 (de) | 2016-05-11 | 2023-06-21 | Cumberland Pharmaceuticals Inc. | Zusammensetzungen und verfahren zur behandlung von muskeldystrophie mit thromboxan-a2-rezeptor-antagonisten |
| CN110833556A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗肝纤维化的用途 |
| MX2022003593A (es) | 2019-09-24 | 2022-09-19 | Mezzion Pharma Co Ltd | Métodos para mejorar el rendimiento del ejercicio, el rendimiento ventricular único y el índice de rendimiento del miocardio (mpi) en la enfermedad cardiaca del ventrículo único, utilizando composiciones de udenafil. |
| CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
| WO2023018972A1 (en) * | 2021-08-13 | 2023-02-16 | Mezzion Pharma Co., Ltd. | Methods and compositions for treating fibrotic liver conditions, using udenafil compositions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19832429A1 (de) * | 1998-07-18 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| KR100353014B1 (ko) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
| TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| KR100377782B1 (ko) | 2000-06-23 | 2003-03-29 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법 |
| US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| GB0202254D0 (en) * | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| EP1336602A1 (de) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrat-Prodrugs zur Freisetzung von Stickstoffmonoxid in kontrollierter und selektiver Weise sowie deren Verwendung zur Prävention und Behandlung inflammatorischer, ischämischer und proliferativer Erkrankungen |
| GB0214784D0 (en) * | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
| WO2004037183A2 (en) | 2002-10-22 | 2004-05-06 | Harbor-Ucla Research And Education Institute | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
| JPWO2004108662A1 (ja) | 2003-05-15 | 2006-07-20 | クミアイ化学工業株式会社 | フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤 |
| DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
| CA2528975A1 (en) * | 2003-06-10 | 2004-12-16 | Pfizer Inc. | Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea |
| DE102005001989A1 (de) | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
-
2005
- 2005-10-21 EP EP05808627A patent/EP1888074B1/de not_active Expired - Lifetime
- 2005-10-21 DK DK05808627.3T patent/DK1888074T3/da active
- 2005-10-21 CN CN2005800500656A patent/CN101193636B/zh not_active Expired - Fee Related
- 2005-10-21 KR KR1020050099900A patent/KR100914445B1/ko not_active Expired - Lifetime
- 2005-10-21 US US11/916,752 patent/US8796286B2/en active Active
- 2005-10-21 BR BRPI0520209-4A patent/BRPI0520209A2/pt not_active IP Right Cessation
- 2005-10-21 PT PT05808627T patent/PT1888074E/pt unknown
- 2005-10-21 AU AU2005332719A patent/AU2005332719B2/en not_active Ceased
- 2005-10-21 RU RU2007149474/15A patent/RU2369392C2/ru active
- 2005-10-21 ES ES05808627T patent/ES2376628T3/es not_active Expired - Lifetime
- 2005-10-21 UA UAA200713931A patent/UA86528C2/uk unknown
- 2005-10-21 MX MX2007015365A patent/MX2007015365A/es active IP Right Grant
- 2005-10-21 WO PCT/KR2005/003526 patent/WO2006132460A1/en not_active Ceased
- 2005-10-21 NZ NZ564369A patent/NZ564369A/en not_active IP Right Cessation
- 2005-10-21 CA CA2611638A patent/CA2611638C/en not_active Expired - Fee Related
- 2005-10-21 AT AT05808627T patent/ATE537832T1/de active
- 2005-10-21 JP JP2008515614A patent/JP4879977B2/ja not_active Expired - Fee Related
-
2007
- 2007-11-26 NO NO20076053A patent/NO20076053L/no not_active Application Discontinuation
- 2007-11-27 IL IL187678A patent/IL187678A/en not_active IP Right Cessation
-
2008
- 2008-01-08 ZA ZA200800180A patent/ZA200800180B/xx unknown
-
2012
- 2012-03-14 CY CY20121100272T patent/CY1112637T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005332719B2 (en) | 2010-05-13 |
| HK1119596A1 (en) | 2009-03-13 |
| KR20060128605A (ko) | 2006-12-14 |
| EP1888074A1 (de) | 2008-02-20 |
| US8796286B2 (en) | 2014-08-05 |
| CA2611638C (en) | 2010-08-24 |
| IL187678A (en) | 2013-04-30 |
| IL187678A0 (en) | 2008-11-03 |
| NZ564369A (en) | 2010-03-26 |
| EP1888074A4 (de) | 2010-06-23 |
| ES2376628T3 (es) | 2012-03-15 |
| CN101193636A (zh) | 2008-06-04 |
| EP1888074B1 (de) | 2011-12-21 |
| PT1888074E (pt) | 2012-03-01 |
| KR100914445B1 (ko) | 2009-08-28 |
| US20080207646A1 (en) | 2008-08-28 |
| JP4879977B2 (ja) | 2012-02-22 |
| WO2006132460A1 (en) | 2006-12-14 |
| CA2611638A1 (en) | 2006-12-14 |
| ZA200800180B (en) | 2009-01-28 |
| RU2007149474A (ru) | 2009-07-20 |
| RU2369392C2 (ru) | 2009-10-10 |
| DK1888074T3 (da) | 2012-01-23 |
| BRPI0520209A2 (pt) | 2009-04-22 |
| CY1112637T1 (el) | 2016-02-10 |
| NO20076053L (no) | 2008-02-27 |
| CN101193636B (zh) | 2011-12-28 |
| MX2007015365A (es) | 2008-02-12 |
| AU2005332719A1 (en) | 2006-12-14 |
| JP2008543748A (ja) | 2008-12-04 |
| UA86528C2 (uk) | 2009-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112637T1 (el) | Παραγων για την προληψη και αγωγη των παθησεων του ηπατος περιεχοντας παραγωγο πυραζολοπυριμιδινης | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| NO20075136L (no) | Nye liposompreparater | |
| SI1611088T1 (sl) | Hidroksamati kot terapevtska sredstva | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| EP1623046A4 (de) | Zusammensetzungen und verfahren zur behandlung von schwerem akutem respiratorischem syndrom (sars) | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| CY1118179T1 (el) | Φαρμακευτικη συνθεση | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| MX2007004765A (es) | Compuestos y metodos que modulan la actividad de la trombopoyetina. | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
| WO2001062799A3 (en) | Method for inhibiting angiogenesis using molecules that enhance plasmin activity | |
| SE0203817D0 (sv) | New composition | |
| MY148300A (en) | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative | |
| WO2010027189A3 (ko) | 호모아이소플라베논 또는 이의 염의 신규한 용도 | |
| SE0202311D0 (sv) | Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment | |
| EA200300368A1 (ru) | Применение аргинина при получении лекарственного средства для профилактики и лечения побочных эффектов, связанных с внутривенным введением фармацевтических препаратов | |
| DE60308862D1 (de) | Verbindungen und zusammensetzungen zur behandlung von diabetes und erkrankungen, die mit diabetes in zusammenhang stehen | |
| ATE491461T1 (de) | Kombinationspräparat zur behandlung der sepsis | |
| ATE454144T1 (de) | Behandlung von malignen neoplasien | |
| ATE477021T1 (de) | 1,3,5-triazepin-dionen zur behandlung von malaria | |
| EA200600987A1 (ru) | Применение сирамезина в лечении злокачественных опухолей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1888074 Country of ref document: EP |